Intravenous XXXX sucrose: establishing a safe dose.

@entity1 @entity390 @entity1307 @entity177 @entity615 @entity551 @entity68
It is now recognized that the majority of @entity1 on @entity1307 therapy require intravenous (IV) @entity68 supplementation to maximize the response to treatment. Of the IV @entity68 preparations available, @entity68 sucrose has proved its efficacy and safety; however, there are no guidelines or systematic studies examining the optimum safe dosage regimen for this compound. The aim of the present study was to investigate prospectively a variety of dosing regimens for IV @entity68 sucrose in @entity1 with @entity177 to develop treatment strategies for this preparation. A total of 335 @entity68 infusions was administered to 249 @entity1 in this study, which was conducted in four phases. In phase I, 89 @entity1 were administered a dose of 200 mg as an IV infusion over 2 hours. No adverse events were seen. A 500-mg dose by 2-hour infusion was then assessed, but was abandoned after 8 of 22 @entity1 developed reactions characterized by dizziness, @entity551 , and @entity390 . The dose was then reduced to 300 mg by 2-hour infusion for the next 189 @entity1 , and again, no adverse reactions were witnessed. Finally, a 400-mg dose by 2-hour infusion was examined in 35 @entity1 , but 2 @entity1 experienced such symptoms as @entity551 , @entity390 , and @entity615 . Both the 200- and 300-mg doses of IV @entity68 sucrose administered over 2 hours appear to be safe. The incidence of adverse events with the 400- and 500-mg doses administered as a 2-hour infusion seems too high to recommend their routine use, although it may be possible to administer these doses over a longer period.
